PHARMACOKINETICS AND EXPOSURE-RESPONSE FOR REGN1979, A BISPECIFIC ANTI-CD20 X ANTI-CD3 ANTIBODY, IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA.

被引：0
|
作者：
Yang, F. [1 ]
Zhu, M. [1 ]
Toroghi, M. [1 ]
Putluri, D. [1 ]
Yan, H. [1 ]
Davis, J. [1 ]
DiCioccio, A. [1 ]
机构：
[1] Regeneron Pharmaceut, New York, NY USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2020年 / 107卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
OV-002
引用
收藏
页码：S120 / S120
页数：1
相关论文
共 50 条
  • [31] Tetravalent anti-CD20/CD3 bispecific antibody for the treatment of B cell lymphoma
    Lu, Chia-Yen
    Chen, Gregory J.
    Tai, Pei-Han
    Yang, Yu-Chen
    Hsu, Yu-Shen
    Chang, Mingi
    Hsu, Chuan-Lung
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (04) : 808 - 813
  • [32] Maintenance therapy using the anti-CD20 antibody Rituximab in patients with B-cell non-Hodgkin lymphoma
    Neumann, F
    Martin, S
    Kronenwett, R
    Fischer, C
    Kondakci, M
    Kobbe, G
    Gattermann, N
    Haas, R
    BLOOD, 2003, 102 (11) : 298B - 298B
  • [33] Anti-CD20 monoclonal antibody therapy for non-Hodgkin's lymphoma (vol 10, pg 108, 1998)
    White, CA
    MINERVA BIOTECNOLOGICA, 1999, 11 (02) : 160 - 160
  • [34] Pretarget radioimmunotherapy (RIT) with anti-CD20 fusion protein in patients with non-Hodgkin's lymphoma (NHL).
    Meredith, R
    Shen, S
    Breitz, H
    Fisher, D
    Goris, M
    Knox, S
    Hankins, J
    Vose, J
    Picozzi, V
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (05) : 116P - 117P
  • [35] Results of a phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma.
    Shah, Nirav Niranjan
    Zhu, Fenlu
    Schneider, Dina
    Taylor, Carolyn
    Krueger, Winfried
    Worden, Andrew
    Longo, Walter L.
    Hamadani, Mehdi
    Fenske, Timothy
    Johnson, Bryon
    Dropulic, Boro
    Orentas, Rimas
    Hari, Parameswaran
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] Targeted anti-cancer therapy using a chimeric anti-CD20 antibody in the treatment of non-Hodgkin's B cell lymphoma
    Anderson, DR
    Varns, C
    IMMUNOLOGY, 1996, 89 : SI112 - SI112
  • [37] In vitro evaluation of pretargeting system with anti-CD20 mAb for targeting non-Hodgkin's lymphoma
    Kim, H.
    Lee, I.
    Shin, E.
    Lee, E.
    Chung, H.
    Shim, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S645 - S646
  • [38] Radioimmunotherapy of B-lineage non-Hodgkin's lymphoma using anti-CD19 and anti-CD20 conjugates.
    Heeger, SW
    Moldenhauer, G
    Flynn, JM
    Egerer, G
    Nikula, T
    Apostolidis, C
    Brechbiel, M
    Haberkorn, U
    Ho, AD
    Haas, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 194S - 194S
  • [39] Treatment of B cell low grade non-Hodgkin's lymphoma (NHL) with anti-CD20 monoclonal antibody Rituximab®
    Federico, M
    Clo, V
    Vinci, G
    Sacchi, S
    ANNALS OF ONCOLOGY, 1998, 9 : 32 - 32
  • [40] Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma:: Safety and efficacy of re-treatment
    Davis, TA
    Grillo-López, AJ
    White, CA
    McLaughlin, P
    Czuczman, MS
    Link, BK
    Maloney, DG
    Weaver, RL
    Rosenberg, J
    Levy, R
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (17) : 3135 - 3143
12345